PT  - JOURNAL ARTICLE
AU  - Michael Benatar
AU  - Lanyu Zhang
AU  - Lily Wang
AU  - Volkan Granit
AU  - Jeffrey Statland
AU  - Richard Barohn
AU  - Andrea Swenson
AU  - John Ravits
AU  - Carlayne Jackson
AU  - Ted M Burns
AU  - Jaya Trivedi
AU  - Erik P Pioro
AU  - James Caress
AU  - Jonathan Katz
AU  - Jacob L McCauley
AU  - Rosa Rademakers
AU  - Andrea Malaspina
AU  - Lyle W Ostrow
AU  - Joanne Wuu
AU  - on behalf of the CReATe Consortium
TI  - Validation of Serum Neurofilaments as Prognostic & Potential Pharmacodynamic Biomarkers for ALS
AID  - 10.1101/19002998
DP  - 2019 Jan 01
TA  - medRxiv
PG  - 19002998
4099  - http://medrxiv.org/content/early/2019/10/10/19002998.short
4100  - http://medrxiv.org/content/early/2019/10/10/19002998.full
AB  - Objective Identify preferred neurofilament assays, and clinically validate serum NfL and pNfH as prognostic and potential pharmacodynamic biomarkers relevant to ALS therapy development.Methods Prospective, multi-center, longitudinal observational study of patients with ALS (n=229), primary lateral sclerosis (PLS, n=20) and progressive muscular atrophy (PMA, n=11). Biological specimens were collected, processed and stored according to strict standard operating procedures (SOPs) 1. Neurofilament assays were performed in a blinded manner by independent contract research organizations (CROs).Results For serum NfL and pNfH measured using the Simoa assay, missing data (i.e. both technical replicates below the lower limit of detection (LLD) was not encountered. For the Iron Horse and Euroimmun pNfH assays, such missingness was encountered in ∼4% and ∼10% of serum samples respectively. Mean coefficients of variation (CVs) for pNfH in serum and CSF were ∼4-5% and ∼2-3% respectively in all assays. Baseline NfL concentration, but not pNfH, predicted the future ALSFRS-R slope and survival.Incorporation of baseline serum NfL into mixed effects models of ALSFRS-R slopes yields an estimated sample size saving of ∼8%. Depending on the method used to estimate effect size, use of serum NfL (and perhaps pNfH) as pharmacodynamic biomarkers, instead of the ALSFRS-R slope, yields significantly larger sample size savings.Conclusions Serum NfL may be considered a clinically validated prognostic biomarker for ALS. Serum NfL (and perhaps pNfH), quantified using the Simoa assay, have potential utility as pharmacodynamic biomarkers of treatment effect.Competing Interest StatementMichael Benatar reports grants from National Institutes of Health, the ALS Association, the Muscular Dystrophy Association, the Centers for Disease Control and Prevention, the Department of Defense, and Target ALS during the conduct of the study; personal fees from Mitsubishi Tanabe Pharma, AveXis, and Genentech, outside the submitted work. In addition, Dr. Benatar has a provisional patent entitled ‘Determining Onset of Amyotrophic Lateral Sclerosis’. Dr. Benatar also serves as a site investigator on clinical trials funded by Biogen and Orphazyme. Lanyu Zhang reports no disclosures. Lily Wang reports grants from the National Institutes of Health during the conduct of the study. Volkan Granit reports no disclosures. Jeffrey Statland reports grants from National Institutes of Health, MDA, and the FSH Society during the conduct of the study; and personal fees from Fulcrum, Acceleron, Strongbridge, Sarepta, and AveXis, outside the submitted work. Richard Barohn reports grants from the National Institutes of Health during the conduct of the study; grants from FDA/OOPD, the ALS Association, the Muscular Dystrophy Association, Sanofi/Genzyme, Biomarin Pharmaceuticals, IONIS Pharmaceuticals, Teva Pharmaceuticals, Cytokinetics Pharmaceuticals, Eli Lilly and Company, PTC Therapeutics, Orphazyme, Neuraltus Pharmaceuticals, Alexion Pharmaceuticals, Sarepta Therapeutics, and The Marigold Foundation outside the submitted work; personal fees from NuFactor, Momenta and Plan 365; and other support from Novartis Pharmaceuticals, Option Care, Platform Q Health Education, Ra Pharma. In addition, Dr. Barohn has patents on the MG-ADL and QMG with royalties paid. Andrea Swenson reports grants from the University of Iowa during the conduct of the study and other support from Amylyx Pharmaceuticals, FlexPharm and Cytokinetics outside the submitted work. John Ravits reports personal fees from MT Pharma and AveXis, outside the submitted work and serves as a site investigator on a clinical trial funded by Biogen. Carlayne Jackson reports grants from the National Institutes of Health, Cytokinetics and Mitsubishi Tanabe Pharma America during the conduct of the study; and personal fees from Mallinckrodt, Brainstorm, Mitsubishi Tanabe Pharma America, ITF Pharma, and Anelixis outside the submitted work. Ted M Burns reports no disclosures. Jaya Trivedi reports grants from National Institutes of Health, Sanofi-Genzyme and CSL Behring during the conduct of the study; as well as personal fees from CSL Behring outside the submitted work. Erik P Pioro reports grants from National Institutes of Health and Center for Disease Control during the conduct of the study; grant support from the ALS Association and CDC/NIH outside the submitted work; as well as personal fees from Avanir Pharmaceuticals, Inc., Biohaven Pharmaceuticals, Inc., Cytokinetics, Inc., ITF Pharma, Inc., MT Pharma America, Inc., and Otsuka America, Inc. James Caress reports grants from National Institutes of Health, Amylyx Pharmaceuticals Inc, Orion Corporation, Cytokinetics Inc, Flex-Pharma and Neurology Clinical Research Initiative TCZALS-001 outside the submitted work. Jonathan Katz reports no disclosures. Jacob L McCauley reports no disclosures. Rosa Rademakers reports no disclosures. Andrea Malaspina reports no disclosures. Lyle W Ostrow reports grants from The Target ALS Foundation and the ALS Association during the conduct of the study. Joanne Wuu reports grants and funding from National Institutes of Health, the ALS Association, the Centers for Disease Control and Prevention, the Department of Defense, and Target ALS during the conduct of the study. Funding StatementThe CReATe Consortium (U54 NS090291) is part of the Rare Diseases Clinical Research Network (RDCRN), an initiative of the Office of Rare Diseases Research (ORDR), National Center for Advancing Translational Sciences (NCATS). CReATe is funded through collaboration between NCATS and the National Institute of Neurological Disorders and Stroke (NINDS). CReATe is also supported by a Clinical Trial Readiness Grant from NIH (U01NS107027). Supplementary support for the CReATe Biorepository was provided by the ALS Association (Grant ID 16-TACL-242). Target ALS provided support to Quanterix and Iron Horse to cover assay costs as well as through a grant to Joanne Wuu. This work was also supported by CTSA grants (UL1TR002366 and UL1TR000001) from NCATS and awarded to the University of Kansas.Author DeclarationsAll relevant ethical guidelines have been followed and any necessary IRB and/or ethics committee approvals have been obtained.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesAny clinical trials involved have been registered with an ICMJE-approved registry such as ClinicalTrials.gov and the trial ID is included in the manuscript.Not ApplicableI have followed all appropriate research reporting guidelines and uploaded the relevant Equator, ICMJE or other checklist(s) as supplementary files, if applicable.YesDe-identified data will be shared immediately following publication.